Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
The restriction of viral receptors and coreceptors to the basolateral surface of airway epithelial cells has been blamed for the inefficient transfer of viral vectors to the apical surface of this tissue. We now report, however, that differentiated human airway epithelia internalize rAAV type-2 virus efficiently from their apical surfaces, despite the absence of known adeno-associated virus-2 (AAV-2) receptors or coreceptors at these sites. The dramatically lower transduction efficiency of rAAV infection from the apical surface of airway cells appears to result instead from differences in endosomal processing and nuclear trafficking of apically or basolaterally internalized virions. AAV capsid proteins are ubiquitinated after endocytosis, and gene transfer can be significantly enhanced by proteasome or ubiquitin ligase inhibitors. Tripeptide proteasome inhibitors increased persistent rAAV gene delivery from the apical surface >200-fold, to a level nearly equivalent to that achieved with basolateral infection. In vivo application of proteasome inhibitor in mouse lung augmented rAAV gene transfer from undetectable levels to a mean of 10.4 +/- 1.6% of the epithelial cells in large bronchioles. Proteasome inhibitors also increased rAAV-2-mediated gene transfer to the liver tenfold, but they did not affect transduction of skeletal or cardiac muscle. These findings suggest that tissue-specific ubiquitination of viral capsid proteins interferes with rAAV-2 transduction and provides new approaches to circumvent this barrier for gene therapy of diseases such as cystic fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro and preclinical animal studies have shown administration of bortezomib prevents degradation of internalized AAVs, reduces capsid presentation, and increases transduction efficiency by enhancing nuclear translocation of AAV [165, 224, 225].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [224]
In the citing paper
“After entry into cells, AAV cells can be ubiquitinated for degradation in proteasomes (91), generating increased amount of antigens for immune activation.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [91]
In the citing paper
“AAV capsids undergo proteosome-mediated degradation in the cytoplasm, which may expose the packaged genomes to cytoplasmic DNA sensors.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [43]
Citations
Cites
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · cited 1×
“Several specific, cellpermeable, peptide aldehyde inhibitors of proteasome pathways have recently been discovered (30, 31).”
BackgroundFenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583 · cited 1×
“Several specific, cellpermeable, peptide aldehyde inhibitors of proteasome pathways have recently been discovered (30, 31).”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“Recently, the heparin sulfate proteoglycan receptor (3), and FGFR-1 (4) and αVβ5 integrin (5) coreceptors for AAV-2, have been localized to the basolateral membrane of polarized airway epithelial cells (6, 7).”
BackgroundMultiple proteolytic systems, including the proteasome, contribute to CFTR processing
Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., & Riordan, J. R. (1995) · Cell · doi:10.1016/0092-8674(95)90241-4 · Cited by 897 · cited 18×
“A similar result was achieved when another ubiquitinproteasome pathway inhibitor, Z-LLL (33), was tested (data not shown).”
BackgroundInfluentialαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547 · cited 2×
“Alternative approaches have attempted to increase transgene expression by enhancing the molecular conversion of nonfunctional viral genomes to expressible forms, as in the case of rAAV (12, 13), or by increasing transcription and translation efficiency by altering the transgene expression cassettes (14).”
BackgroundDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 2×
“It has been previously shown that AAV transduction in certain tissues such as muscle and retina is very efficient (16, 38), whereas other tissues including lung and liver are less favorably transduced (6, 39).”
BackgroundMethodSelf-citationThe Ubiquitin-Proteasome Pathway and Pathogenesis of Human Diseases
Schwartz, P., & Ciechanover, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.57 · Cited by 466 · cited 2×
“Regulated intracellular proteolysis through proteasomes plays a critical role in many physiological and pathological conditions (35).”
BackgroundSamulski, R. J., Chang, L. S., & Shenk, T. (1987) · Journal of Virology · doi:10.1128/jvi.61.10.3096-3101.1987 · Cited by 449 · cited 1×
“The entire β-galactosidase expression cassette, including the RSV promoter, β-galactosidase reporter gene, and SV40 polyA signal, was excised by Sal I digestion and subsequently cloned into the pSub201 backbone by blunt-end ligation (18).”
MethodHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Research works printed but not linked: 3
- Zabner, 1996, Gene Ther, 3, 458
- Hughes, 1993, Lab Invest, 69, 173
- Bennett, 1997, Invest Ophthalmol Vis Sci, 38, 2857
Cited by
Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis
Gibson, R. L., Burns, J. L., & Ramsey, B. W. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200304-505so · Cited by 1,633
“Coadministration of AAV2 with a proteosome inhibitor (449) results in improved transgene expression and augmented nuclear trafficking of the virus.”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“uitination of the intact virus can occur during transport to the nucleus [73].”
BackgroundAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“Early studies by Engelhardt and colleagues 89,90 showed that AAV vector particles are indeed ubiquitinated once internalized in the cytosol, a step that is fundamental for targeting intracellular proteins for degradation through More than 50% of humans develop anti-AAV humoral immunity after the…”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Metadata
- Authors
- Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Engelhardt, John F.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-06-01
- Volume
- 105
- Issue
- 11
- Pages
- 1573-1587
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC300848
- OpenAlex
- W1970138286
- Cited by
- 391
- References
- 45
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 5 · 2020: 9 · 2019: 17 · 2018: 6 · 2017: 9 · 2016: 4 · 2015: 11 · 2014: 10 · 2013: 18 · 2012: 18
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK54759)
- National Heart, Lung, and Blood Institute (R01HL058340)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54759, P30DK054759)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- adeno-associated virus type 2, airway epithelium, endosomal processing, proteasome inhibitors, ubiquitin ligase inhibitors, nuclear trafficking, pulmonary gene therapy, cystic fibrosis
- MeSH terms
- Dependovirus, Animals, Bronchi, Capsid, Cells, Cultured, Cysteine Endopeptidases, Egtazic Acid, Epithelial Cells, Humans, Lung, Mice, Inbred BALB C, Multienzyme Complexes, Endosomes, Ubiquitins, Genetic Therapy, Cell Polarity, Gene Transfer Techniques, Proteasome Endopeptidase Complex, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.